This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NexMed Appoints Dr. Stephen B. Howell, World Renowned Key Opinion Leader In Oncology As Chairman Of Its Scientific Advisory Board

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT ® technology, today announced the appointment of Stephen B. Howell, M.D., as Chairman of its Scientific Advisory Board.

Commenting on today’s news, Dr. Bassam Damaj, Chief Executive Officer of NexMed, noted, “We are very pleased to welcome Steve as Chairman of our Scientific Advisory Board. He is recognized as a world-class, key opinion leader in oncology and his expertise will be especially valuable as we continue the development of our cancer therapies.”

Dr. Howell currently serves as a medical oncologist and Professor of Medicine at the University of California, San Diego. He also serves as Associate Director for Clinical Research and Director of the Cancer Therapeutics Training Program at the Moores Comprehensive Cancer Center at the University of California, San Diego, and runs the Clayton Foundation Drug Resistance Laboratory at the Cancer Center. During his career, Dr. Howell has co-founded three pharmaceutical companies, including DepoTech (1989), Beacon Laboratories (1995), and Targa Pharmaceuticals (2003), serving as Medical Director of each.

Dr. Howell holds a number of patents for his innovative work in chemotherapeutics, drug-delivery systems, and diagnostic assays and is the recipient of numerous awards, including the Milken Family Medical Foundation Award for Outstanding Work in the Field of Cancer Research, a presidential citation from the American Head and Neck Society, and a Fogarty Senior International Fellowship. He is currently one of the main organizers of the American Association of Cancer Research.

Dr. Howell is a graduate of Harvard Medical School and is board certified in internal medicine and medical oncology. He completed his internship, residency, and medical oncology training at the Massachusetts General Hospital, the University of California, San Francisco, and the Dana Farber Cancer Institute, respectively. He completed his research training at the National Institutes of Health.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AAPL $132.25 1.50%
FB $82.15 0.76%
GOOG $555.22 -1.70%
TSLA $232.32 6.40%
YHOO $44.44 -0.18%


DOW 18,073.64 -6.50 -0.04%
S&P 500 2,114.74 -2.95 -0.14%
NASDAQ 5,071.74 -20.3450 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs